CSIMarket
 
Teva Pharmaceutical Industries Limited  (NYSE: TEVA)
 
Price: $36.0800 $-0.27 -0.743%
Day's High: $36.75 Week Perf: -0.77 %
Day's Low: $ 36.06 30 Day Perf: -1.8 %
Volume (M): 365,133 52 Wk High: $ 38.37
Volume (M$): $ 0 52 Wk Avg: $30.43
Open: $36.46 52 Wk Low: $18.21



 Market Capitalization (Millions $) 42,033
 Shares Outstanding (Millions) 1,165
 Employees 33,950
 Revenues (TTM) (Millions $) 14,105
 Net Income (TTM) (Millions $) 709
 Cash Flow (TTM) (Millions $) 1,580
 Capital Exp. (TTM) (Millions $) 887

Business Description


Teva Pharmaceutical Industries Limited is a global pharmaceutical company that specializes in the development, manufacture, and distribution of generic drugs, specialty medicines, and active pharmaceutical ingredients. The company was founded in Jerusalem, Israel in 1901, and has since grown to become one of the largest pharmaceutical companies in the world, with operations in more than 60 countries.

Teva's portfolio of products includes a wide range of generic and branded drugs, including medications for chronic and acute conditions, injectable drugs, biosimilars, and over-the-counter medicines. The company's size and scale allow it to offer affordable medications for a diverse range of conditions, helping to ensure that patients have access to the treatments they need.

In addition to its core business of manufacturing and distributing pharmaceuticals, Teva is also involved in drug development and research. The company has an R&D team dedicated to developing new drugs and technologies, with a particular focus on therapeutic areas such as central nervous system disorders, respiratory diseases, and oncology.

Teva is committed to environmental sustainability and ethical business practices. The company has implemented various programs to reduce its environmental impact, such as reducing water and energy use, and minimizing waste. Teva is also dedicated to promoting patient safety and ethical conduct, and has established strong compliance and ethics programs to ensure that all employees act with integrity and adhere to the highest ethical standards.

Teva employs more than 42,000 people worldwide and has a revenue of over $16 billion. The company is headquartered in Petah Tikva, Israel and operates manufacturing facilities all over the world, including in the United States, Europe, and Asia. Teva has an extensive global distribution network, allowing it to reach patients in nearly every corner of the world.


   Company Address: 400 Interpace Parkway, #3 NJ 7054
   Company Phone Number: 658-0301   Stock Exchange / Ticker: NYSE TEVA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
JNJ   -3.42%    
MRK   -5.04%    
OGN   -0.91%    
PFE   -4.46%    
VRTX   -8.07%    
VTRS   -2.95%    
• View Complete Report
   



Clinical Study

Teva Pharmaceuticals Unveils Groundbreaking Safety Data for Olanzapine LAI, Paving the Way for Safer Schizophrenia Tr...

Published Mon, Sep 22 2025 2:37 AM UTC

Breaking New Ground in Schizophrenia Treatment: Teva Pharmaceuticals Presents Promising Long-term Safety Data from the SOLARIS Trial Teva Pharmaceuticals, a prominent player in the global pharmaceutical market and a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), recently made waves in the psychiatric medicine landscape with the presentation of new l...

Product Service News

Tevas Triple Triumph New Weight Loss Drug, Mental Health Funding, and New Cancer Treatment Offer Hope,

Published Fri, Aug 29 2025 6:42 PM UTC

Teva s Triple Triumph: Major Launches, Strategic Commitments, and Expanded Healthcare Access In an inspiring showcase of pharmaceutical innovation and social responsibility, Teva Pharmaceuticals has announced a series of strategic initiatives and product launches that promise to significantly impact public healthcare. Among these announcements are the FDA approval of a gene...

Clinical Study

Unveiling the Silent Crisis Teva Pharmaceuticals Exposes Alarming Rates of Undertreated Tardive Dyskinesia in Long-Te...

Published Sat, May 31 2025 10:14 AM UTC

In a groundbreaking presentation at Psych Congress Elevate 2025, Teva Pharmaceuticals has unveiled new data revealing significant rates of undertreated tardive dyskinesia (TD) among patients in long-term care (LTC) settings. This announcement is particularly timely and critical, as it brings to light the profound implications of inadequate diagnosis and treatment within this...

Management Announcement

Teva Pharmaceuticals Strategic Shift Pays Off: Fitch Upgrades Rating Amid Promising Duvakitug Developments

Published Tue, May 20 2025 8:30 PM UTC

In a notable development for Teva Pharmaceuticals, Fitch Ratings Agency has upgraded the company s rating to BB+, acknowledging its effective pivot towards a growth strategy that has begun to bear fruit. This strategic transformation, coupled with the recent promising data from the Phase 2b clinical trial of Duvakitug, Teva’s innovative therapy in partnership with Sanofi f...

Clinical Study

Unveiling Duvakitug’s Promise Teva and Sanofi Showcase Compelling Phase 2b Data at ECCO 2025

Published Sun, Feb 23 2025 10:31 AM UTC

: Recent developments in the pharmaceutical landscape concerning autoimmune diseases like Ulcerative Colitis (UC) and Crohn’s Disease (CD) have spotlighted Duvakitug an innovative anti-TL1A monoclonal antibody co-developed by Teva Pharmaceuticals and Sanofi. The new Phase 2b study results presented at the European Crohn’s and Colitis Organisation (ECCO) 2025 conference...




Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 59.28
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 2.98
Price to Sales (Expected) -
Price to Book 5.42
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.23
Working Capital Ratio 0.88
Leverage Ratio (MRQ) 4.14
Total Debt to Equity 2.14
Interest Coverage (TTM) -
Debt Coverage (TTM) 0.12

Per Share Current
Earnings (TTM) 0.61 $
Revenues (TTM) 12.11 $
Cash Flow (TTM) 1.36 $
Cash 3.14 $
Book Value 6.66 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 415,464
Net Income per Employee (TTM) 20,884
Receivable Turnover Ratio (TTM) 3.92
Inventory Turnover Ratio (TTM) 3.66
Asset Turnover Ratio (TTM) 0.3

Profitability Ratios Current
Gross Margin (MRQ) 51.98 %
Operating Margin (MRQ) -5.58 %
Net Margin (MRQ) -13.88 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) 1.69 %

Management Effectiveness Current
Return On Assets (TTM) 1.51 %
Return On Investment (TTM) 2.66 %
Return On Equity (TTM) 9.11 %
Dividend Yield -
Pay out Ratio (TTM) -



Teva Pharmaceutical Industries Limited's Segments
US    78.13 % of total Revenue
Europe    62.84 % of total Revenue
International Markets    25.93 % of total Revenue
Other activities    29.24 % of total Revenue
Product    168.78 % of total Revenue
License    1.86 % of total Revenue
Distribution Service    20.04 % of total Revenue
Product and Service Other    5.46 % of total Revenue
United States Segment    78.13 % of total Revenue
Europe Segment    62.84 % of total Revenue

  Teva Pharmaceutical Industries Limited Outlook

On December 20 2024 the Teva Pharmaceutical Industries Limited provided following guidance

nnTeva Pharmaceutical Industries Limitednn is set to provide an update on its financial performance and expectations for the future in a significant conference call. The company has announced that it will release its financial results for the fourth quarter and the full year of 2024, alongside its financial outlook for 2025, on Wednesday, January 29, 2025, at 7:00 a.m. Eastern Time.

Investors and s alike are keenly awaiting this announcement, as the details regarding the financial guidance for 2025 will be disclosed during the event. While Teva has confirmed that it will offer insights into its future financial outlook, it has yet to provide any specific figures or projections. This lack of detailed...





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.